uniQure NV
Closed
44.56 0.72
Overview
Share price change
24h
Min
44.19
Max
45
Income | -28M -81M |
|---|---|
Sales | 2.3M 5.8M |
EPS | -1.22 |
Profit margin | -1,387.759 |
Employees | 221 |
EBITDA | -34M -70M |
Next Earnings | 9 Nov 2026 |
|---|
Market Cap | 460M 3.1B |
|---|---|
Previous open | 43.84 |
Previous close | 44.56 |
uniQure NV Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
uniQure NV Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.